ProKidney Corp. promotes Dr. Farah Ali to Chief Medical Officer to lead clinical programs for chronic kidney disease treatments.
Quiver AI Summary
ProKidney Corp. has promoted Dr. Farah Ali to the position of Chief Medical Officer, where she will oversee the clinical program and lead the pivotal Phase 3 PROACT 1 study of the cell therapy rilparencel, aimed at addressing chronic kidney disease (CKD). CEO Bruce Culleton praised Dr. Ali's extensive clinical development background and her understanding of the urgent need for innovative treatments. Dr. Ali has over a decade of experience in the biopharmaceutical field, having previously held senior roles at Immunovant, Amgen, and Horizon Therapeutics, focusing on various therapeutic areas. In her new role, Dr. Ali aims to advance the clinical foundation for rilparencel and prepare for the company's growth as it seeks to improve kidney function for patients with advanced CKD and type 2 diabetes.
Potential Positives
- Dr. Farah Ali's promotion to Chief Medical Officer positions ProKidney for enhanced leadership and strategic direction in its clinical programs.
- The advancement of the Phase 3 PROACT 1 study represents a significant step towards the potential commercialization of rilparencel, which could offer new treatment options for patients with chronic kidney disease.
- Dr. Ali's extensive experience in clinical development within the biopharmaceutical industry may improve the company's ability to navigate drug development challenges and regulatory requirements.
- The company's innovative approach to addressing advanced CKD could differentiate it in a competitive market and have a positive impact on patient outcomes.
Potential Negatives
- The press release highlights the need for new treatment options for patients with chronic kidney disease, suggesting the current options may be inadequate or insufficient.
- There is a risk of the company's clinical trials not yielding supportive results for regulatory approval, which could significantly hinder the company's growth and market entry for its lead product.
- The press release mentions the company's reliance on future financing, which poses a risk to its operational continuity and could affect investor confidence.
FAQ
Who was promoted to Chief Medical Officer at ProKidney?
Farah Ali, M.D., M.S., has been promoted to the role of Chief Medical Officer at ProKidney Corp.
What is the main focus of ProKidney Corp.?
ProKidney focuses on developing innovative cell therapies for chronic kidney disease (CKD).
What study is ProKidney advancing?
ProKidney is advancing the pivotal Phase 3 PROACT 1 study of rilparencel.
What is rilparencel?
Rilparencel is a first-in-class, patented autologous cell therapy aimed at preserving kidney function.
What does Farah Ali aim to achieve in her new role?
Farah Ali aims to advance the PROACT 1 program and build the clinical foundation for rilparencel.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$PROK Insider Trading Activity
$PROK insiders have traded $PROK stock on the open market 6 times in the past 6 months. Of those trades, 0 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $PROK stock by insiders over the last 6 months:
- BRIAN JG PEREIRA has made 0 purchases and 6 sales selling 757,164 shares for an estimated $1,067,773.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$PROK Hedge Fund Activity
We have seen 55 institutional investors add shares of $PROK stock to their portfolio, and 50 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. added 2,774,468 shares (+53.4%) to their portfolio in Q3 2026, for an estimated $4,605,616
- PROPEL BIO MANAGEMENT, LLC added 2,009,733 shares (+inf%) to their portfolio in Q3 2026, for an estimated $3,336,156
- ARTIA GLOBAL PARTNERS LP removed 1,253,195 shares (-69.4%) from their portfolio in Q3 2026, for an estimated $2,080,303
- GEODE CAPITAL MANAGEMENT, LLC added 1,200,832 shares (+50.2%) to their portfolio in Q3 2026, for an estimated $1,993,381
- RENAISSANCE TECHNOLOGIES LLC removed 1,082,800 shares (-98.5%) from their portfolio in Q3 2026, for an estimated $1,797,448
- MARSHALL WACE, LLP removed 1,011,744 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $2,063,957
- SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. removed 781,729 shares (-100.0%) from their portfolio in Q3 2026, for an estimated $1,297,670
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$PROK Analyst Ratings
Wall Street analysts have issued reports on $PROK in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Citigroup issued a "Buy" rating on 10/28/2026
To track analyst ratings and price targets for $PROK, check out Quiver Quantitative's $PROK forecast page.
Full Release
WINSTON-SALEM, N.C., Nov. 18, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today announced the promotion of Farah Ali, M.D., M.S., to the role of Chief Medical Officer. Dr. Ali will lead the clinical program and team as ProKidney advances the pivotal Phase 3 PROACT 1 study of rilparencel and progresses toward potential commercialization.
“Farah’s clinical background and drug development experience give her a unique perspective on the challenges patients face and the urgent need for new treatment options for individuals living with CKD,” said Bruce Culleton, M.D., Chief Executive Officer of ProKidney. “We are thrilled to recognize her contributions with this appointment and expanded leadership role as we work to advance a potential new treatment for patients living with advanced CKD and type 2 diabetes.”
Dr. Ali brings more than a decade of experience in clinical development and medical affairs across the biopharmaceutical industry, with a focus on advancing innovative therapies through clinical development, regulatory submissions, and product lifecycle management. Prior to joining ProKidney, she served as Senior Vice President, Clinical Development at Immunovant, where she led clinical development in endocrinology and rheumatology. Previously, she served as Vice President, Clinical Development for Rare Disease at Amgen and Vice President, Clinical Development at Horizon Therapeutics, where she specialized in rare and autoimmune diseases.
Throughout her career, Dr. Ali has led multiple clinical development programs across diverse disease states, including global development programs involving both biologic and small-molecule therapies. She has also held leadership roles in clinical development and global medical affairs at AbbVie and Baxter Healthcare.
Dr. Ali began her career in academic medicine, serving on the faculty at Northwestern University Feinberg School of Medicine, where she conducted clinical research and provided patient care. She earned a Bachelor of Arts in Molecular and Cell Biology from the University of California, Berkeley, and both her M.D. and Master of Science in Clinical Investigation from Northwestern University. She completed her residency and fellowship training at Northwestern University and is board certified in pediatric nephrology.
“ProKidney is pursuing a differentiated approach to addressing advanced CKD, with the potential to preserve kidney function and help patients delay the need for dialysis,” said Farah Ali, M.D., M.S., Chief Medical Officer of ProKidney. “I look forward to continuing to work alongside the team as we advance the PROACT 1 program, continue building the clinical and medical foundation for rilparencel, and prepare for the next stage of the Company’s growth.”
About ProKidney Corp.
ProKidney, a pioneer in the treatment of CKD through innovations in cell therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, rilparencel (also known as REACT
®
), is a first-in-class, patented, proprietary autologous cell therapy with regenerative medicine advanced therapy designation that is being evaluated in the ongoing Phase 3 REGEN-006 (PROACT 1) study for its potential to preserve kidney function in patients with advanced CKD and type 2 diabetes. For more information, please visit
www.prokidney.com
.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. ProKidney’s actual results may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the achievement and timing of the topline data readout of the Company’s Phase 3 PROACT 1 trial and other milestones provided, the Company’s beliefs that the PROACT 1 trial could be sufficient to support a potential BLA submission and full regulatory approval, the Company’s belief that eGFR slope can be used as a surrogate endpoint on an accelerated approval pathway for rilparencel, expectations with respect to financial results and expected cash runway, including the Company’s expectation that current cash, cash equivalents and marketable securities will support operating plans into mid-2027, the Company’s ability to continue as a going concern, future performance, development, manufacturing, and commercialization of products, if approved, the potential benefits and impact of the Company’s products, if approved, potential regulatory approvals, the size and potential growth of current or future markets for the Company’s products, if approved, the advancement of the Company’s development programs into and through the clinic and the expected timing for reporting data, the making of regulatory filings or achieving other milestones related to the Company’s product candidates, and the advancement and funding of the Company’s developmental programs, generally. These statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with: disruptions to the Company’s business or that may otherwise materially harm its results of operations or financial condition as a result of its domestication to the United States; the inability to maintain the listing of the Company’s Class A common stock on Nasdaq; the inability of the Company’s Class A common stock to remain included in various indices and the potential negative impact on the trading price of the Class A common stock if excluded from such indices; the inability to implement business plans, forecasts, and other expectations or identify and realize additional opportunities, which may be affected by, among other things, competition and the ability of the Company to grow and manage growth profitably and retain its key employees; the risk of downturns and a changing regulatory landscape in the highly competitive biotechnology industry; the risk that results of the Company’s clinical trials may not support approval; the risk that the FDA could require additional studies before approving the Company’s drug candidates; the Company’s need for additional financing and the inability of the Company to raise financing in the future; the inability of the Company to obtain and maintain regulatory clearance or approval for its products, and any related restrictions and limitations of any cleared or approved product; the inability of the Company to identify, in-license or acquire additional technology; the inability of the Company to compete with other companies currently marketing or engaged in the biologics market and in the area of treatment of kidney diseases; the size and growth potential of the markets for the Company’s products, if approved, and its ability to serve those markets, either alone or in partnership with others; the Company’s estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the Company’s financial performance; the Company’s intellectual property rights; uncertainties inherent in cell therapy research and development, including the actual time it takes to initiate and complete clinical studies and the timing and content of decisions made by regulatory authorities; the fact that interim results from the Company’s clinical programs may not be indicative of future results; the impact of geopolitical conflict on the Company’s business; and other risks and uncertainties included under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. The Company cautions readers that the foregoing list of factors is not exclusive and cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.
ProKidney Contact
Ethan Holdaway
[email protected]
Media Contact
Audra Friis
[email protected]
Investor Relations Contact
Daniel Ferry
[email protected]